Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug - PubMed (original) (raw)

Review

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

Iskandar Idris et al. Diabetes Obes Metab. 2009 Feb.

Abstract

The sodium-glucose co-transporter-2 (SGLT2) is a low-affinity transport system that is specifically expressed in the kidney and plays an important role in renal glucose reabsorption in the proximal tubule. Competitive inhibition of SGLT2 therefore represents an innovative therapeutic strategy for the treatment of hyperglycaemia and/or obesity in patients with type 1 or type 2 diabetes by enhancing glucose and energy loss through the urine. The observation that individuals with familial renal glycosuria maintain normal long-term kidney function provides some reassurance that this mode of action will not adversely affect renal function. Intense research in this therapeutic area has led to the discovery of novel SGLT2 inhibitors, each with different chemical, pharmacodynamic and pharmacokinetic profiles. This review outlines the biology, expression and pleotropic activity of the SGLT system and the pharmacological profile of SGLT2 inhibitors and provides a summary of preclinical and limited clinical data available to characterize the efficacy, safety and potential clinical utility of SGLT2 inhibitors in the management of diabetes.

PubMed Disclaimer

Cited by

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K; EMBLEM Trial Investigators. Tanaka A, et al. Cardiovasc Diabetol. 2017 Apr 12;16(1):48. doi: 10.1186/s12933-017-0532-8. Cardiovasc Diabetol. 2017. PMID: 28403850 Free PMC article. Clinical Trial.
SGLT inhibitors as antidiabetic agents: a comprehensive review.
Kshirsagar RP, Kulkarni AA, Chouthe RS, Pathan SK, Une HD, Reddy GB, Diwan PV, Ansari SA, Sangshetti JN. Kshirsagar RP, et al. RSC Adv. 2020 Jan 9;10(3):1733-1756. doi: 10.1039/c9ra08706k. eCollection 2020 Jan 7. RSC Adv. 2020. PMID: 35494673 Free PMC article. Review.
Thyroid stimulating hormone stimulates the expression of glucose transporter 2 via its receptor in pancreatic β cell line, INS-1 cells.
Lyu J, Imachi H, Yoshimoto T, Fukunaga K, Sato S, Ibata T, Kobayashi T, Dong T, Yonezaki K, Yamaji N, Kikuchi F, Iwama H, Ishikawa R, Haba R, Sugiyama Y, Zhang H, Murao K. Lyu J, et al. Sci Rep. 2018 Jan 31;8(1):1986. doi: 10.1038/s41598-018-20449-3. Sci Rep. 2018. PMID: 29386586 Free PMC article.
The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Chen J, Fan F, Wang JY, Long Y, Gao CL, Stanton RC, Xu Y. Chen J, et al. Sci Rep. 2017 Mar 9;7:44128. doi: 10.1038/srep44128. Sci Rep. 2017. PMID: 28276512 Free PMC article. Review.
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease.
Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Campos-Murguía A, et al. World J Gastroenterol. 2020 Oct 21;26(39):5919-5943. doi: 10.3748/wjg.v26.i39.5919. World J Gastroenterol. 2020. PMID: 33132645 Free PMC article. Review.

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug - PubMed (original) (raw)